<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 18, 1996
Roberts Pharmaceutical Corporation
-------------------------------------------------------
(Exact name of registrant as specified in its charter)
New Jersey 1-10432 22-2429994
- --------------- ----------- --------------
(State or other (Commission (IRS Employer
jurisdiction File Number) Identification
of incorporation) Number)
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
----------------------------------------------------------------
(Address of principal executive office, including zip code)
Registrant's telephone number, including area code: (908) 389-1182
-------------------------------------------------------------------
(Former name or former address, if changed since last report.)
<PAGE>
Item 5. Other Events.
-------------
On July 18, 1996, Mr. John T. Spitznagel was elected a Vice President and
a Director of Roberts Pharmaceutical Corporation. Mr. Spitznagel is responsible
for worldwide sales and marketing. Prior to joining Roberts, Mr. Spitznagel held
senior level positions with Reed and Carnick Pharmaceuticals, Wyeth Laboratories
and Hoffmann-La Roche. Mr. Spitznagel holds a Master of Business Administration
degree (Magna Cum Laude) from Fairleigh Dickinson University.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly cased this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Roberts Pharmaceutical Corporation
----------------------------------
(Registrant)
By: /s/ Anthony A. Rascio
-------------------------------
Anthony A. Rascio
Vice President
Date: July 26, 1996
